These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7751691)

  • 1. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
    van Leeuwen R; Katlama C; Kitchen V; Boucher CA; Tubiana R; McBride M; Ingrand D; Weber J; Hill A; McDade H
    J Infect Dis; 1995 May; 171(5):1166-71. PubMed ID: 7751691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
    Pluda JM; Cooley TP; Montaner JS; Shay LE; Reinhalter NE; Warthan SN; Ruedy J; Hirst HM; Vicary CA; Quinn JB
    J Infect Dis; 1995 Jun; 171(6):1438-47. PubMed ID: 7769277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
    Lewis LL; Venzon D; Church J; Farley M; Wheeler S; Keller A; Rubin M; Yuen G; Mueller B; Sloas M; Wood L; Balis F; Shearer GM; Brouwers P; Goldsmith J; Pizzo PA
    J Infect Dis; 1996 Jul; 174(1):16-25. PubMed ID: 8655986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
    van Leeuwen R; Lange JM; Hussey EK; Donn KH; Hall ST; Harker AJ; Jonker P; Danner SA
    AIDS; 1992 Dec; 6(12):1471-5. PubMed ID: 1283519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
    Ingrand D; Weber J; Boucher CA; Loveday C; Robert C; Hill A; Cammack N
    AIDS; 1995 Dec; 9(12):1323-9. PubMed ID: 8605051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3TC approved: now for the tough questions.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):6-8. PubMed ID: 11363101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
    Kavlick MF; Shirasaka T; Kojima E; Pluda JM; Hui F; Yarchoan R; Mitsuya H
    Antiviral Res; 1995 Oct; 28(2):133-46. PubMed ID: 8585767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3TC/AZT: just another combination.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early markers of HIV infection and subclinical disease progression.
    Dolan MJ; Lucey DR; Hendrix CW; Melcher GP; Spencer GA; Boswell RN
    Vaccine; 1993; 11(5):548-51. PubMed ID: 8098175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine (3TC) approved for combination use with AZT.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
    Schuurman R; Nijhuis M; van Leeuwen R; Schipper P; de Jong D; Collis P; Danner SA; Mulder J; Loveday C; Christopherson C
    J Infect Dis; 1995 Jun; 171(6):1411-9. PubMed ID: 7539472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3TC and AZT.
    Treat Rev; 1995; (no 17):2. PubMed ID: 11362294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.